GLYSURE APPOINTS JUSTINE MCQUILLAN AS EUROPEAN DIRECTOR OF CLINICAL AFFAIRS

September 25, 2013, Oxfordshire, England: GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, today announced the appointment of Justine McQuillan as its European Director of Clinical Affairs. In this newly established position, McQuillan is leading European clinical regulatory trials of GlySure's CBGM technology, which the company expects to complete this fall.

McQuillan has extensive clinical, operational and commercial experience within the MedTech industry, with expertise in the development, evaluation and validation, regulatory clearance and marketing of medical devices and supporting services. She spent eight years at Medicsight PLC, having most recently served as Vice President of Clinical Development. In this role, McQuillan planned, implemented and managed the clinical regulatory strategy to support European, U.S., Chinese and Japanese submissions for regulatory clearance of the company's computer-aided detection medical image analysis products.

"McQuillan's knowledge and experience in successfully guiding a company from R&D through regulatory trials and all the way through to commercialization are the exact qualities we need at this critical juncture of our development," said GlySure CEO Chris Jones. "In addition to leading efforts to secure a CE mark, McQuillan will be working closely with our U.S. trial sites to prepare for U.S. FDA 510(k) regulatory trials."

McQuillan holds a Master of Business Administration from the University of Westminster, London, a Post-graduate Diploma in Management from University of London, and a Diploma in Medical Diagnostic Imaging from Auckland School of Radiography, New Zealand.

###Ends###

Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235 462 870. [email protected]

Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: 508-314-3127. [email protected]

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.